PRINCETON, N.J., Jan. 22, 2015 /PRNewswire/ -- Derma Sciences, Inc. (Nasdaq:DSCI), a tissue regeneration company focused on advanced wound care, announces that AMNIOEXCEL® and AMNIOMATRIX®, amniotic allografts derived from placental tissues, have been added to the Premier, Inc. Regenerative Skin Grafting contract portfolio. The announcement increases the opportunity for the AMNIOEXCEL® and AMNIOMATRIX® product lines, which continue to be adopted by clinicians in many health care facilities, including Veterans Administration and Military Hospitals, to be used in patient care.
"Amniotic tissue technology facilitates excellent clinical outcomes with difficult, non-healing wounds," said Edward Eisenlord, Vice President of Corporate Accounts at Derma Sciences. "We are thrilled that more doctors and patients will benefit from access to these fairly priced advanced skin substitute products." This new agreement offers Premier alliance members access to Derma Sciences' complete amniotic allograft product line.
"Derma Sciences' Amniotic Allograft products have shown impressive clinical results on my patients," said Dr. Dimitrios Lintzeris, Wayne Memorial Hospital, Goldsboro, NC. "The ability to use AMNIOEXCEL® and/or AMNIOMATRIX®, depending on my patients' wound management needs, is very beneficial to my practice."
"This partnership with Premier, Inc. is an important milestone for our Amniotic Allograft product line as we continue to expand our presence as a leader in the tissue regeneration market," said Barry Wolfenson, Group President, Advanced Wound Care and Product Development at Derma Sciences. "As industry front-runners, we are always looking for ways to expand access and reach more patients with our advanced treatment options. This partnership with Premier, Inc. will help us get there."
ABOUT AMNIOEXCEL®
AMNIOEXCEL® is an Amniotic Allograft Membrane used on challenging and non-healing wounds. As a dehydrated human amnion-derived tissue allograft, AMNIOEXCEL® maintains the natural, inherent properties of the native tissue including an intact extracellular matrix and growth factors. It provides a structural tissue for the repair, replacement or reconstruction of damaged skin. AMNIOEXCEL® is a natural alternative to synthetics and xenografts, is flexible and conformable to the wound bed, and is not side-specific in its application.
ABOUT AMNIOMATRIX®
AMNIOMATRIX® is derived from the components of the amniotic membrane and amniotic fluid recovered from living donors after a full term pregnancy. It was developed using a proprietary CryoPrime™ process, which preserves the structural properties of the collagen, cytokines, growth factors, inherent matrix and cellular materials.
Both AMNIOEXCEL® and AMNIOMATRIX® have expansive access and availability to the healthcare market including being listed on the VA Federal Supply Schedule (FSS), which ensures product availability in VA and military medical centers, outpatient clinics and community living centers across the U.S.
ABOUT DERMA SCIENCES, INC.
Derma Sciences is a tissue regeneration company focused on advanced wound and burn care. It offers a line of products with patented technologies to help better manage chronic and hard-to-heal wounds, many of which result from diabetes and poor vascular functioning. The company recently entered the $500 million market for skin substitute products with its licensing of AMNIOEXCEL® and AMNIOMATRIX® in the first quarter of 2014. AMNIOEXCEL® was launched to customers in March 2014 and AMNIOMATRIX ® was launched in the second quarter. Its MEDIHONEY® product is the leading brand of honey-based dressings for the management of wounds and burns. The product has been shown in clinical studies to be effective in a variety of indications. TCC-EZ® is its gold-standard total contact casting system for diabetic foot ulcers. Other novel products introduced into the $14 billion global wound care market include XTRASORB® for better management of wound exudate, and BIOGUARD® for barrier protection against microbes and other contaminants. Its pharmaceutical wound care products include DSC127, which is currently in Phase 3 clinical trials for the healing of diabetic foot ulcers. The drug candidate is also part of a BARDA grant program for the healing/prevention of tissue damage due to ionizing radiation exposure. The patented API peptide used in DSC127 is also in preclinical testing for scar prevention/reduction. The company also offers a full product line of traditional dressings.
For more information please visit www.dermasciences.com.
ABOUT Premier, Inc.
Premier, Inc. is a leading healthcare improvement company, uniting an alliance of approximately 3,400 U.S. hospitals and 110,000 other providers to transform healthcare. With integrated data and analytics, collaboratives, supply chain solutions, and advisory and other services, Premier enables better care and outcomes at a lower cost. Premier, a Malcolm Baldrige National Quality Award recipient, plays a critical role in the rapidly evolving healthcare industry, collaborating with members to co-develop long-term innovations that reinvent and improve the way care is delivered to patients nationwide. Headquartered in Charlotte, N.C., Premier is passionate about transforming American healthcare. Please visit Premier's news and investor sites on www.premierinc.com; as well as Twitter, Facebook, LinkedIn, YouTube, Instagram, Foursquare and Premier's blog for more information about the company.
Derma Sciences Forward-Looking Statement
Statements contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release or that are otherwise made by or on behalf of the Company. Factors that may affect the Company's results include, but are not limited to development and commercialization of DSC127, product demand, market acceptance, impact of competitive products and prices, product development, completion of an acquisition, the success or failure of negotiations and trade, legal, social and economic risks. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include but are not limited to, those discussed in the Company's filings with the U.S. Securities and Exchange Commission.
CONTACT:
Derma Sciences, Inc.
Barry Wolfenson, (609) 514-4744
Group President, Advanced Wound Care and Pharmaceutical Development
bwolfenson@dermasciences.com
or
Investors
LHA
Kim Sutton Golodetz, (212) 838-3777
kgolodetz@lhai.com
or
Bruce Voss, (310) 691-7100
bvoss@lhai.com
or
Media
Spectrum Science Communications
Leticia Diaz, (202) 955-6222
ldiaz@spectrumscience.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/derma-sciences-expands-access-of-its-amniotic-tissue-product-line-with-new-premier-inc-agreement-300024252.html
SOURCE Derma Sciences, Inc.
